PA
XRAY icon

PharVision Advisers’s Dentsply Sirona XRAY Stock Holding History

PharVision Advisers’s Portfolio XRAY Stock Details XRAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,526
Closed -$375K – 1042
2025
Q3 		$375K Buy
29,526
+11,874
+67% +$172K 0.21% 104
2025
Q2 		$280K Buy
+17,652
New +$264K 0.4% 95

Other funds holding XRAY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

PharVision Advisers's XRAY Position: Q4 2025 in Review

PharVision Advisers sold out of Dentsply Sirona (XRAY) in Q4 2025, closing a stake of 29,526 shares — an estimated $375K sold.

PharVision Advisers first reported a position in XRAY in Q2 2025 and held it in 2 quarters. The position peaked at $375K in Q3 2025. 362 funds tracked by Wall St. Rank hold XRAY as of Q4 2025.

  • PharVision Advisers reported no remaining Dentsply Sirona position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 29,526 Dentsply Sirona shares in Q4 2025, an estimated $375K.
  • PharVision Advisers first reported a position in Dentsply Sirona in Q2 2025 and held it in 2 quarters.
  • PharVision Advisers's Dentsply Sirona position peaked at $375K in Q3 2025.
  • 362 funds tracked by Wall St. Rank held Dentsply Sirona as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.